Effective management of severe cutaneous mastocytosis in young children with omalizumab (Xolair® )

J D M Hughes; T Olynyc; H Chapdelaine; L Segal; B Miedzybrodzki; M Ben-Shoshan

doi:10.1111/ced.13408

Effective management of severe cutaneous mastocytosis in young children with omalizumab (Xolair^® )

Clin Exp Dermatol. 2018 Jul;43(5):573-576. doi: 10.1111/ced.13408. Epub 2018 Feb 16.

Authors

J D M Hughes¹, T Olynyc², H Chapdelaine³, L Segal⁴, B Miedzybrodzki⁵, M Ben-Shoshan^{5

6}

Affiliations

¹ University of Ottawa - Department of Medicine, Ottawa, Ontario, Canada.
² Department of Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada.
³ Department of Medicine, Centre Hospitalier Universitaire de Montreal, Montreal, Quebec, Canada.
⁴ Department of Medicine, Community Pediatrics, University of Ottawa, Ottawa, Ontario, Canada.
⁵ Department of Pediatrics, Division of Allergy and Clinical Immunology and Dermatology, Department of Pediatrics, Montreal Children's Hospital, Montreal, Quebec, Canada.
⁶ Department of Medicine, Division of Experimental Medicine, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.

PMID: 29451318
DOI: 10.1111/ced.13408

Abstract

Omalizumab (Xolair^® ) is an anti-IgE monoclonal antibody, which may benefit adults with systemic mastocytosis. We report effective treatment with omalizumab in two toddlers with severe diffuse cutaneous mastocytosis. Our cases offer preliminary evidence to support the safe use of omalizumab in paediatric patients with cutaneous mastocytosis.

Publication types

Case Reports

MeSH terms

Anti-Allergic Agents / therapeutic use*
Child, Preschool
Humans
Male
Mastocytosis, Cutaneous / drug therapy*
Omalizumab / therapeutic use*

Substances

Anti-Allergic Agents
Omalizumab